Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma

Expression of Class I Histone Deacetylases Indicates Poor Prognosis in Endometrioid Subtypes of Ovarian and Endometrial Carcinomas

(2015) Wilko Weichert et al.   NEOPLASIA

Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDAC

(2013) Sridurga Mithraprabhu et al.   BRITISH JOURNAL OF HAEMATOLOGY

HDAC6 promotes hepatocellular carcinoma progression by inhibiting P53 transcriptional activity

(2013) Gang Ding et al.   FEBS LETTERS

The functional interactome landscape of the human histone deacetylase family

(2013) P. Joshi et al.   Molecular Systems Biology

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

(2012) L. Santo et al.   BLOOD

HDAC isoenzyme expression is deregulated in chronic lymphocytic leukemia B-cells and has a complex prognostic significance

(2012) Michaël Van Damme et al.   Epigenetics

HDAC11 is a novel drug target in carcinomas

(2012) Hedwig E. Deubzer et al.   INTERNATIONAL JOURNAL OF CANCER

Histone deacetylases and cancer

(2012) Bruna Barneda-Zahonero et al.   Molecular Oncology

Class IIa HDACs: from important roles in differentiation to possible implications in tumourigenesis

(2011) Andrea Clocchiatti et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms

(2011) Vibe Skov et al.   LEUKEMIA & LYMPHOMA

Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma

(2011) T. Hideshima et al.   MOLECULAR CANCER THERAPEUTICS

Initial genome sequencing and analysis of multiple myeloma

(2011) Michael A. Chapman et al.   NATURE

Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma

(2010) J. Kikuchi et al.   BLOOD

research paper: Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia

(2010) Daniel Antunes Moreno et al.   BRITISH JOURNAL OF HAEMATOLOGY

The DAC system and associations with multiple myeloma

(2010) Enrique M. Ocio et al.   INVESTIGATIONAL NEW DRUGS

The Role of HDAC6 in Cancer

(2010) Grace I. Aldana-Masangkay et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

Regulating the Regulators: The Post-Translational Code of Class I HDAC1 and HDAC2

(2010) Chiara V. Segré et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas

(2009) Lena Marquard et al.   HISTOPATHOLOGY

Expression Levels of Histone Deacetylases Determine the Cell Fate of Hematopoietic Progenitors

(2009) Taeko Wada et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy

(2008) W Weichert et al.   BRITISH JOURNAL OF CANCER

HDAC expression and clinical prognosis in human malignancies

(2008) Wilko Weichert   CANCER LETTERS

HDAC family: What are the cancer relevant targets?

(2008) Olaf Witt et al.   CANCER LETTERS

Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases In vitro and In vivo

(2008) W. Weichert et al.   CLINICAL CANCER RESEARCH

Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma

(2008) L Marquard et al.   HISTOPATHOLOGY

Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis

(2008) Wilko Weichert et al.   LANCET ONCOLOGY

Enhanced histone deacetylase enzyme activity in primary myelofibrosis

(2008) Jen Chin Wang et al.   LEUKEMIA & LYMPHOMA

HDAC4 Promotes Growth of Colon Cancer Cells via Repression of p21

(2008) Andrew J. Wilson et al.   MOLECULAR BIOLOGY OF THE CELL

The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance

(2008) Alejandro Villagra et al.   NATURE IMMUNOLOGY

The many roles of histone deacetylases in development and physiology: implications for disease and therapy

(2008) Michael Haberland et al.   NATURE REVIEWS GENETICS

HDAC4 represses p21WAF1/Cip1 expression in human cancer cells through a Sp1-dependent, p53-independent mechanism

(2008) D Mottet et al.   ONCOGENE